Biotechnology

Adhera Therapeutics, Inc.

Adhera Therapeutics, Inc. released FY2022 Q4 earnings on March 31, 2023 (EST), with revenue of 0 and EPS of -0.1201

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ACRS

ATRX

PHOE

ARKG

LABU

SBIO

Phoenix Asia Holdings Limited shares rose 0.19% on Thursday following the announcement of a $1 billion stock acquisition of ACEA Pharma. This deal, involving 100 million newly-issued shares at $10 each, is expected to close by Q2 2026, pending regulatory approvals. The acquisition aims to expand Phoenix Asia's footprint in the pharmaceutical sector, potentially creating new revenue streams. Despite mixed market conditions, the stock's momentum remains bullish, although it trades at a premium compared to peers, indicating potential valuation risks for investors.

benzinga_article

Aclaris Therap

Phoenix Asia

SPDR S&P Biotech

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

VG Health

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

NASDAQ Composite Index

S&P 500

Dow Jones Industrial Average

Why Is Phoenix Asia Stock Gaining Today?

Adheris Health Grants 60 Million Long-Dated Employee Options

Tip Ranks

Adheris Health Grants 60 Million Long-Dated Employee Options

ALIT

Rosen Law Firm is reminding investors who purchased Alight, Inc. (NYSE: ALIT) common stock between November 12, 2024, and February 18, 2026, of the May 15, 2026, lead plaintiff deadline for a securities fraud class action lawsuit. Investors may be entitled to compensation without upfront fees. The lawsuit alleges that Alight misrepresented its growth potential and financial stability, leading to investor losses when the truth emerged. Interested parties can contact the firm for more information on joining the class action.

prnewswire

Alight

17:46 ETALIT Investors Have Opportunity to Lead Alight, Inc. Securities Fraud Lawsuit

AUPH

Affinia Therapeutics has received approval from Health Canada to initiate the UPBEAT© trial, a Phase 1/2 clinical trial for AFTX-201, aimed at treating BAG3-associated dilated cardiomyopathy (DCM). AFTX-201 is designed to address the genetic cause of BAG3 DCM with a one-time intravenous administration. The trial will evaluate the safety and efficacy of AFTX-201, following its acceptance by the FDA and receiving Fast Track designation. The UPBEAT trial will include multiple sites in the U.S. and Canada, focusing on patients with genetically confirmed BAG3 DCM.

MorningStar

Aurinia Pharma

Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)

ABCL

In the third quarter of 2026, the Phase II study for diabetes treatment is anticipated to reveal its topline data. The ASC30 showed promising results with a placebo-adjusted weight loss of a maximum of 7.7% in a 13-week U.S. Phase II study involving individuals struggling with obesity or being overweight. This indicates a significant improvement in managing weight-related issues.

Unusual Whales

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Abcellera Biologics

Ascletis starts Phase II study with ASC30 in US for diabetes treatment. Expect data in Q3 2026. ASC30 shows up to 7.7% weight loss in 13-week study with overweight individuals.

LABD

Ascletis Pharma Inc. has announced the dosing of the first participants in a 13-week Phase II study of ASC30, an oral GLP-1 receptor agonist for type 2 diabetes. Topline data is expected in Q3 2026. Previous studies showed ASC30 achieved significant weight loss with good gastrointestinal tolerability. The Phase II study will evaluate ASC30's efficacy, safety, and tolerability in approximately 100 participants, with a focus on changes in HbA1c and body weight compared to placebo.

iShares US Pharma

Direxion S&P Biotech Bear 3X

19:10 ET
			
			
				Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes

NBSE.ESC

On January 20, 2026, Genezen, a top gene therapy Contract Development and Manufacturing Organization (CDMO) based in Lexington, Massachusetts, and Atsena Therapeutics, a clinical-stage gene therapy company from Durham, North Carolina, announced a collaboration. Atsena Therapeutics aims to harness the transformative potential of genetic treatments. The partnership allows Genezen to provide its expertise in gene therapy manufacturing to support Atsena Therapeutics. This collaboration signifies a significant step forward in advancing gene therapy research and development efforts.

ESC NEUBASE THERAPEUTI

iShares US Medical Devices

Genezen and Atsena form strategic manufacturing partnership in Jan 2026. Genezen is a gene therapy CDMO, Atsena is a clinical gene therapy company.

Adhera Therapeutics, Inc.(ATRX.US)

Why Is Phoenix Asia Stock Gaining Today?

Adheris Health Grants 60 Million Long-Dated Employee Options

17:46 ETALIT Investors Have Opportunity to Lead Alight, Inc. Securities Fraud Lawsuit

Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)

Ascletis starts Phase II study with ASC30 in US for diabetes treatment. Expect data in Q3 2026. ASC30 shows up to 7.7% weight loss in 13-week study with overweight individuals.

19:10 ET Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes

Genezen and Atsena form strategic manufacturing partnership in Jan 2026. Genezen is a gene therapy CDMO, Atsena is a clinical gene therapy company.